ClinicalTrials.gg
CompletedNCT01306643Updated Nov 19, 2018Results posted

Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma

A Phase 1/2 interventional study of Idelalisib in Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma and Small Lymphocytic Lymphoma, sponsored by Gilead Sciences. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-19.

Sponsored by Gilead Sciences · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing idelalisib in Lymphoma, Follicular — none open to participants now, none under way, none of them phase 3. idelalisib · Lymphoma, Follicular.

Enrollment
6th of 12
18 · median 18
Started
2011
with 1 other
Phase 1/2
Only one
of the 12
Registered
2nd of 12
by date
Lead sponsor
7 of 12
Gilead Sciences

Among the 12 studies testing idelalisib in Lymphoma, Follicular, this one is the 6th largest by enrollment, is one of 2 that started in 2011, is the only one in phase 1/2, and was the 2nd registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

None of the 12 studies testing idelalisib in Lymphoma, Follicular is open now. The open studies under Lymphoma, Follicular, anywhere →

About idelalisib

idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing idelalisib in Lymphoma, Follicular as a file.
02

Study summary

The primary objectives of this study is to evaluate the safety and efficacy of idelalisib (GS-1101, CAL-101) in participants with previously treated indolent non-Hodgkin lymphoma (iNHL).

Eligible patients will initiate oral therapy with idelalisib at a starting dose of 150 mg twice per day. Treatment with idelalisib can continue in compliant participants for up to twelve 28-day cycles of idelalisib. Participants who appear to be benefiting from treatment at the completion of 12 cycles of treatment with idelalisib may be eligible for participation in a long-term safety extension study of idelalisib.

03

Conditions studied

  • Indolent Non-Hodgkin's Lymphoma
  • Follicular Lymphoma
  • Small Lymphocytic Lymphoma
  • Marginal Zone Lymphoma

Keywords

  • Indolent Non-Hodgkin's Lymphoma
  • Non-Hodgkin Lymphoma
  • iNHL
  • NHL
  • CAL-101
  • PI3K
  • Phosphatidylinositol 3-kinase
  • Follicular Lymphoma (FL)
  • Small Lymphocytic Lymphoma (SLL)
  • Marginal Zone Lymphoma (MZL)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously treated B-cell iNHL
  • Provide written

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing
  • Active, serious infection requiring systemic therapy
  • Positive test for antibodies
  • Active or C viral infection
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Idelalisib

    Drug: Idelalisib

Interventions

  • Tablet(s) administered orally twice daily

    Also known as: GS-1101, CAL-101, Zydelig®

06

What researchers measure

Primary outcomes

  1. Overall Safety of Idelalisib

    The overall safety of idelalisib was assessed as the percentage of participants experiencing treatment-emergent adverse events (AEs; Serious AEs, Grade ≥ 3 AEs, AEs related to idelalisib, and AEs leading to discontinuation of idelalisib).

    Time frame: 30 days post last study treatment (up to 12 months)

  2. Clinical Response: Overall Response Rate

    Participants were assessed for clinical response by appropriate imaging at the end of cycles 3, 6, 9, and 12. Overall response rate (ORR) was assessed based on standardized criteria (Cheson 2007), and was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) based on investigator assessment after the start of idelalisib treatment until progression or the end of study drug treatment. * CR was defined as the disappearance of all evidence of disease. * PR was defined the regression of measurable disease and no new sites.

    Time frame: Up to twelve 28-day cycles (maximum of 12 months)

Secondary outcomes

  1. Flow Cytometric Measurement of Constitutive or Inducible Phosphorylation of Akt (at S473) and S6 Within Tumor B Cells

    Time frame: Up to twelve 28-day cycles (maximum of 12 months)

  2. Flow Cytometric Measurement of Tumoral and Peripheral Blood T and NK Cells

    Time frame: Up to twelve 28-day cycles (maximum of 12 months)

  3. Changes in Concentration of Peripheral Blood Chemokines and Cytokines

    Time frame: Up to twelve 28-day cycles (maximum of 12 months)

  4. Changes in Liver Imaging as Assessed by Magnetic Resonance Imaging (MRI) and Gadoxetic Acid (GD-EOB-DTPA) Contrast

    Time frame: Up to twelve 28-day cycles (maximum of 12 months)

07

Results

Posted Dec 21, 2016

Participant flow

Participants were enrolled at 2 study sites in the United States. The first participant was screened on 22 February 2011. The last study visit occurred on 24 August 2015.

Participant flow — Overall Study
MilestoneIdelalisib
Started18
Completed5
Not completed13
Withdrew: Adverse event5
Withdrew: Disease progression7
Withdrew: Other: change in eligibility status1

Outcome measures

PrimaryOverall Safety of Idelalisib

The overall safety of idelalisib was assessed as the percentage of participants experiencing treatment-emergent adverse events (AEs; Serious AEs, Grade ≥ 3 AEs, AEs related to idelalisib, and AEs leading to discontinuation of idelalisib).

Time frame:
30 days post last study treatment (up to 12 months)
Reported as:
Number · percentage of participants
Overall Safety of Idelalisib
percentage of participantsIdelalisib
Any AE88.9
Serious AE27.8
Grade ≥ 3 AE55.6
AE related to idelalisib83.3
AE leading to permanent drug discontinuation27.8
PrimaryClinical Response: Overall Response Rate

Participants were assessed for clinical response by appropriate imaging at the end of cycles 3, 6, 9, and 12. Overall response rate (ORR) was assessed based on standardized criteria (Cheson 2007), and was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) based on investigator assessment after the start of idelalisib treatment until progression or the end of study drug treatment. * CR was defined as the disappearance of all evidence of disease. * PR was defined the regression of measurable disease and no new sites.

Time frame:
Up to twelve 28-day cycles (maximum of 12 months)
Reported as:
Number · percentage of participants
Clinical Response: Overall Response Rate
percentage of participantsIdelalisib
Clinical Response: Overall Response Rate44.4 (21.5 to 69.2)
SecondaryFlow Cytometric Measurement of Constitutive or Inducible Phosphorylation of Akt (at S473) and S6 Within Tumor B Cells
Time frame:
Up to twelve 28-day cycles (maximum of 12 months)

No measurements were reported for this outcome.

SecondaryFlow Cytometric Measurement of Tumoral and Peripheral Blood T and NK Cells
Time frame:
Up to twelve 28-day cycles (maximum of 12 months)

No measurements were reported for this outcome.

SecondaryChanges in Concentration of Peripheral Blood Chemokines and Cytokines
Time frame:
Up to twelve 28-day cycles (maximum of 12 months)

No measurements were reported for this outcome.

SecondaryChanges in Liver Imaging as Assessed by Magnetic Resonance Imaging (MRI) and Gadoxetic Acid (GD-EOB-DTPA) Contrast
Time frame:
Up to twelve 28-day cycles (maximum of 12 months)

No measurements were reported for this outcome.

Adverse events

Collected over 30 days post last study treatment (up to 12 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Idelalisib—5/18 (27.8%)15/18 (83.3%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventIdelalisib
Tumour lysis syndromeMetabolism and nutrition disorders2/18
Renal failureRenal and urinary disorders2/18
Atrial fibrillationCardiac disorders1/18
Gastrointestinal haemorrhageGastrointestinal disorders1/18
CellulitisInfections and infestations1/18
SepsisInfections and infestations1/18
Alanine aminotransferase increasedInvestigations1/18
Aspartate aminotransferase increasedInvestigations1/18
Transaminases increasedInvestigations1/18
HypoxiaRespiratory, thoracic and mediastinal disorders1/18
Most frequent other events
Showing 10 of 101
Most frequent other events
EventIdelalisib
DiarrhoeaGastrointestinal disorders8/18
FatigueGeneral disorders8/18
Alanine aminotransferase increasedInvestigations8/18
Aspartate aminotransferase increasedInvestigations8/18
NauseaGastrointestinal disorders7/18
VomitingGastrointestinal disorders5/18
PyrexiaGeneral disorders5/18
InsomniaPsychiatric disorders5/18
RashSkin and subcutaneous tissue disorders5/18
Upper respiratory tract infectionInfections and infestations4/18

Baseline characteristics

Intent-to-treat (ITT) Analysis Set: all enrolled participants who received at least 1 dose of idelalisib.

Age, Continuous
Age, Continuous(years)Idelalisib
Mean58 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)Idelalisib
Female8
Male10
Diagnosis
Diagnosis(participants)Idelalisib
Follicular lymphoma10
Marginal zone lymphoma3
Small lymphocytic lymphoma4
Missing1
08

Study locations

2 sites
  • Stanford Cancer Center
    Palo Alto, California 94304-5548, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
09

References and documents

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2016, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2011
First posted
Mar 2, 2011
Start
Feb 2011
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Results first posted
Dec 21, 2016
Last update
Nov 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01306643
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Mar 2, 2011
Start date
Feb 2011
Primary completion
Aug 2015
Completion
Aug 2015
Results posted
Dec 21, 2016
Last update
Nov 19, 2018

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Idelalisib

Start the discussion